Completed

Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Fat Emulsion 2%

+ Fat Emulsion 20%

Drug
Who is being recruted

Blood-Borne Infections+22

+ Urogenital Diseases

+ Genital Diseases

From 18 to 60 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorAbbott
Last updated: February 20, 2009
Sourced from a government-validated database.Claim as a partner

To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.

NCT00002029
Principal SponsorAbbott
Last updated: February 20, 2009
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBody WeightBody Weight ChangesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsOpportunistic InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSigns and SymptomsSigns and Symptoms, DigestiveSlow Virus DiseasesPathological Conditions, Signs and SymptomsVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeHyperphagiaWeight LossHIV InfectionsAIDS-Related Opportunistic Infections

Criteria

Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). All drugs used for the standard treatment of opportunistic infections. Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry. Patients must have: Diagnosis of AIDS. Weight loss of > 10 percent premorbid body weight. Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma. Require home total parenteral nutrition (TPN) for a period of approximately 3 months. Life expectancy = or > 90 days. Prior Medication: Allowed: Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Patients with the following are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Prior Medication: Excluded within 3 months of study entry: Immunomodulators. Experimental antiviral DT. History of drug abuse.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Intracare Inc

Miami, United StatesOpen Intracare Inc in Google Maps

East Orange Veterans Administration Med Ctr

East Orange, United States
Completed2 Study Centers